Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Kirsten Fischer • 14 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Obinutuzumab Venetoclax
CLL14

Kirsten Fischer of the University of Cologne, Cologne, Germany, discusses data on a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and coexisting comorbidities. Dr Fischer presents the results of the CLL14 study (NCT02242942), with a particular emphasis on efficacy and MRD data. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals